Biogen Pharmachem Industries Limited has issued an official postal ballot notice for shareholder voting on major corporate actions, including a 1:6 bonus share issue and significant capital structure changes. The company has set a comprehensive voting timeline with the e-voting period scheduled from March 27 to April 25, 2026.

Postal Ballot Timeline and Process

The company has established a detailed calendar for the postal ballot process, with all key dates clearly defined for shareholder participation.

Bonus Share Issuance Details

The board has recommended issuing fully paid-up bonus shares in a 1:6 ratio, providing shareholders with 1 new equity share for every 6 existing shares held. The bonus issue will create approximately 15,04,33,833 new equity shares of Rs. 1 each, funded through the company's securities premium account.

Capital Structure Changes

The board approved increasing the company's authorized share capital substantially to accommodate future growth and the bonus issue.

Statutory Auditor Appointment

The postal ballot includes approval for appointing M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot as statutory auditors to fill the casual vacancy. M/s. Rishi Sekhri & Associates Chartered Accountants resigned from their position due to significant medical conditions, with the resignation taking effect from February 9, 2026.

E-Voting Process and Shareholder Rights

The company will conduct the postal ballot exclusively through electronic voting via NSDL's e-voting platform. Shareholders whose names appear in the register of members or beneficial owners list as on the cut-off date of March 20, 2026, are eligible to participate in the voting process.

The voting covers three ordinary resolutions: approval for bonus share issue in 1:6 ratio, increase in authorized share capital from Rs. 91,00,00,000 to Rs. 1,08,00,00,000 with consequent alteration of Clause V of the Memorandum of Association, and appointment of statutory auditors.

Regulatory Compliance and Documentation

M/s. Daksha Negi & Associates, Practicing Company Secretaries, has been appointed as the scrutinizer for conducting the voting process. The company has ensured full compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable regulations.

The bonus shares, once allotted, will rank pari-passu with existing equity shares and carry identical rights. Shareholders will be entitled to participate in dividends and other corporate actions declared after the new shares are allotted. The company maintains adequate reserves with securities premium available totaling Rs. 17,00,00,000, providing sufficient coverage for the required Rs. 15,04,33,833 for bonus implementation.

Biogen Pharmachem Industries Limited has formally notified the stock exchange about an upcoming board meeting to consider the declaration of bonus shares. The meeting represents a significant corporate development that could benefit existing shareholders through additional equity allocation.

Board Meeting Details

The company has scheduled the board meeting with specific parameters and regulatory compliance requirements:

Regulatory Compliance and Approval Process

The bonus share declaration falls under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has emphasized that the proposed bonus share issuance will be implemented in accordance with applicable provisions and remains subject to shareholder approval.

The formal intimation was communicated to BSE Limited, where the company trades under scrip code 531752. Wholetime Director Kelash Bunkar signed the official notification, ensuring proper corporate governance protocols are followed.

Company Information

Biogen Pharmachem Industries Limited operates with CIN number L51100GJ1995PLC026702, indicating its incorporation in Gujarat in 1995. The company maintains its registered office at Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001.

The bonus share consideration represents a potential value addition for existing shareholders, as such declarations typically indicate the company's confidence in its financial position and future prospects. However, the final decision will depend on board deliberations and subsequent shareholder approval through the prescribed corporate governance process.